Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (August 2024)
27 slides from Pulse Biosciences's investor presentation, Aug 12, 2024
Slide 1: Investor Presentation August 2024
(@) Pulse Biosciences’ Investor Presentation ‘August 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Al statements in this presentation that are not histrial ace forward.boking statements inching, among other things, statements rebating to the effectiveness of the Company's CalEX naro-PFA technology and Cell System to nor-thermaly clea cells while spering adjacent non-cll
Slide 3: Advancing ablation therapy with next-generation Nanosecond Pulsed Field technology
Advancing ablation therapy with next- generation Nanosecond Pulsed Field technology to deliver health innovation that improves the quality of life for patients and benefits clinician users.
Slide 4: Ablation is a Ubiquitous Treatment Modality
Ablation is a Ubiquitous Treatment Modality Widely adopted procedures used by a diverse set of clinicians for the treatment of many disease states soncen However, it is challenging to precisely c ——— control where ablative energy is delivered Cardin Arrnythmias Skin Cancer Lung Cancer Liver Cancer C
Slide 5: Pulsed Field Ablation Represents an Ablation Breakthrough
Pulsed Field Ablation Represents an Ablation Breakthrough Cardiac Arrhythmias Skin Condition Pulsed Field Ablation (PFA) technology is being rapidly adopted in electrophysiology due to ease of use, speed and improved clinical outcomes for patients Skin Cancer Lung car ver Cancer Chronic Bronchitis a
Slide 6: Pulse Biosciences' Nanosecond Pulsed Field Ablation is the Next Generation of PFA
Pulse Biosciences’ Nanosecond Pulsed Field Ablation ( is the Next Generation of PFA Microsecond PFA Long Duration, Low Amplitude x Constrains or limits electrode and catheter design (requires point electrodes) X Limited ablation depth X Requires multiple energy deliveries {D) Pulse Biosciences: ¥ Co
Slide 7: Fundamental & Novel Innovation
Fundamental & Novel Innovation V Differentiated approach focused on novel Y Continued development and patent filings covering therapy development systems, applications, and methods of combining nanosecond pulsing with other biological technologies and agents Richard Nuccitelli, Ph.D., Pulse Bioscien
Slide 8: Largest Preclinical Library of nano-PFA Histology in the World
Largest Preclinical Library of nano-PFA Histology in the World : a Nano-PFA technology delivers ‘These energy pulses cause the This disruption triggers significant ultrafast energy pulses creation of tiny pores whi changes deep within cellular allows ions to move within organelles leading to regulat
Slide 9: Experienced Technologists, Operators and Clinicians
Experienced Technologists, Operators and Clinicians Form Proven Leadership Team President & Chief Executive Officer Established Board of Directors Ca {D) Pulse Biosciences:
Slide 10: Pioneering a Faster, More Predictable and Easier-to-Use Ablation Therapy
Pulse Biosciences is Pioneering a Faster, More Predictable and Easier-to-Use Ablation Therapy Focused on improving the standard of care in currently iden’ reaching significant areas of unmet clinical need Proven nano-PFA applications Dermatology f Dermatology System | ¥FDA510(k) Glearance for soft t
Slide 11: Versatility of nano-PFA Technology Delivered Across the Anatomy
Versatility of nano-PFA Technology Delivered Across the Anatomy hrough a single console compatible with all Pulse devices + Cloud-enabled analytics * Allows software-tunable treatment settings for each different clinical application * Tracks utilization {D) Pulse Biosciences:
Slide 12: Focused on Delivering Novel Nano-PFA Therapies for Patients
Focused on Delivering Novel Nano-PFA Therapies for Patients 1. Solid Clinical Evidence Development. * Validate clinical performance via high-quality studies Strong Foundation for Commercial Adoption * Allow for marketing the device as a specific treatment option rather than as a tool * The ability t
Slide 13: Clinical Regulatory Commercial
Clinical Regulatory Commercial Soft Tissue Feasibility in benign thyroid completed * Received FDA 510(k) dearance for soft tissue ablation * Initiated pilot program for aiaaticn Plan to continue benign thyroid crical in March of 2024 soft tissue ablation in 2024 : Studies thoughout 2024-2025 + Plant
Slide 14: (D PulseBiosciences
(D PulseBiosciences cuncarunmscxmannemreeremes 1
Slide 15: Benign Thyroid Nodule Market Size of 1.3M Patients Worldwide
Benign Thyroid Nodule Market Size of 1.3M Patients Worldwide Total Worldwide Benign Benign Thyroid Nodule Ablation Market Size Thyroid Nodule Ablation * Approximately 3 in 4 patients undergoing Opportunity 2023 sas thyroidectomy have benign thyroid nodules Est. 1.3M WW Patients? * Itis estimated tha
Slide 16: Transforming the Thyroidectomy Market
Transforming the Thyroidectomy Market Minimally Invasive * Completed treatments in FIH Feasibility Study * Preclinical and clinical data demonstrating initial safety * Rapid ablation of tissue * 8 seconds per ablation zone (nano zone) * Promising initial results; volume and symptom reduction FDA 510
Slide 17: Successful Patient Treatments in FIH Study
Successful Patient Treatments in FIH Study Before nano-PFA 30 Days After Procedure Reduced Nodule Volume Leads to improved cosmesis compared to surgical resection Leads to symptom reduction
Slide 18: Pilot Commercial Program Guided by Experienced Clinicians
Pilot Commercial Program Guided by Experienced Clinicians Soft Tissue Ablation ¥ Commencing pilot US commercial launch under 510(k) soft tissue ablation indication Launch is led by KOLs to ensure and enhance adoption campaign: Y Currently partnering with leading clinicians Y Plan to conduct investig
Slide 19: FDA Breakthrough Device Designation
“FDA Breakthrough Device Designation Enrolled in the FDA’s Total Product Life Cycle Advisory Program (TAP)* cunasrumscmmannemrerenes 19
Slide 20: Addressing the Growing AF Market Through Surgical Ablation
Addressing the Growing AF Market Through Surgical Ablation AF Patients 2019: ~43M Global* Expected 2050; + WW Total Concomitant Market Opportunity = >$ ~ " Est. tients 72M Global Surgical Ablation * An estimated 1.5M open heart procedures are sh performed each year worldwide® * ~30% of open-heart pa
Slide 21: Pulse's Cardiac Ablation Clamp
Pulse’s Cardiac Ablation Clamp @|_ Bipolar Clamp Sy 4)2-Day Histology: Gomeritrcheame stan showing tasted ts through theleft atrial appendagein s percinemocel
Slide 22: Planned U.S. Regulatory Pathway Underway
Planned U.S. Regulatory Pathway Underway v Received FDA Breakthrough Device Designation in July 2024 * For the ablation of cardiac tissue for the treatment of AF * Designation speeds up assessment and review for premarket approval Y Enrolled in the FDA’s Total Product Life Cycle (TPLC) Advisory Prog
Slide 23: {(D) PulseBiosciences:
{(D) PulseBiosciences: cuncasrumscxmannemrecrenes 22
Slide 24: Addressing the Growing AF Market with Catheter Ablation
Addressing the Growing AF Market with Catheter Ablation Global Atrial Fibrillation YY, (AF) Disease State: AF Patients 2019: ~43M Global* >$8B Expected 2050: “72M Global* Electrophysiology Market Catheter Ablation ayy >1M Catheter Ablations Performed Per Year
Slide 25: Customized nano-PFA Electrode Design
Customized nano-PFA Electrode Design 2-Day Endocardial Surface Sem Diameter (Porcine)
Slide 26: Cardiac Catheter Feasibility Study Preliminary Results
360 Cardiac Catheter Feasibility Study Preliminary Results N=46 Remap Results 60-90 Days Post Treatment Total of 39 patients treated at Homolce Hospital, Prague Avg. Ablation Time PVI (n=24) : 10.7 min Expanding clinically to additional patients in Prague and sites in Europe Plans to initiate discus
Slide 27: Pulse Summary
Pulse Summary In pre-clinical testing, Decelared clin ealtared ters Demonstrated nano-PFA has ; operational and significant advantages using nano-PFA commercial over microsecond PFA capabilities Dermatology — initial clinical indication Soff tissue ablation needle ~ (} commercial pilot program under
Pulse Biosciences — Investor Presentation (August 2024) on 6ix